Etentamig for Relapsed Multiple Myeloma: New Bispecific Shows Strong Results, Low CRS | IMS 2026

Peter Voorhees, MD, of Atrium Health Levine Cancer Institute discusses phase 3 CERVINO results for etentamig, a new BCMA bispecific antibody, at IMS 2026 in Glasgow. In patients with at least two prior lines of therapy, etentamig improved response, progression-free survival and overall survival compared with standard treatment. He explains what makes its design different, why rates of cytokine release syndrome and neurotoxicity were low, and how less frequent dosing could help community practices use it.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity

Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:

0:00 Introduction: Dr. Peter Voorhees, Atrium Health Levine Cancer Institute

0:20 Introducing Etentamig: A New BCMA Bispecific

0:40 What Makes Etentamig's Design Different

1:25 Phase 1 Results: Response Rate and Safety

2:11 The CERVINO Phase 3 Trial Design

2:43 CERVINO Results: Response and Survival Benefit

3:26 Safety Results: Low CRS and ICANS Rates

4:14 Preventing CRS with Tocilizumab

4:38 Why Less Frequent Dosing Could Help Community Practices